This inventor holds 2 USPTO granted patents. Top assignees: Astra Zeneca U.k. Limited, Zeneca Limited. Active years: 2001-2005.
Company Filing History:
Years Active: 2001-2005
Title: Michael Derek Edge: Innovator in Cancer Therapy
Introduction
Michael Derek Edge is a notable inventor based in Macclesfield, GB. He has made significant contributions to the field of cancer therapy through his innovative work on monoclonal antibodies. With a total of 2 patents, Edge's research focuses on the development of therapeutic agents that can aid in the diagnosis and treatment of cancer.
Latest Patents
Michael Derek Edge's latest patents include a monoclonal antibody to carcinoembryonic antigen (CEA) and its conjugates for therapeutic use. The anti-CEA monoclonal antibody, designated 806.077, is of murine origin and is particularly useful for cancer diagnosis and therapy. The antibody's complementarity determining regions feature specific sequences that enhance its effectiveness. Additionally, the antibody can be humanized and formulated as a conjugate with enzymes or co-stimulatory molecules, further expanding its therapeutic potential.
Career Highlights
Throughout his career, Edge has worked with prominent companies such as AstraZeneca UK Limited and Zeneca Limited. His experience in these organizations has allowed him to refine his expertise in the development of innovative cancer therapies.
Collaborations
Michael Derek Edge has collaborated with notable professionals in his field, including Stephen Charles Emery and Clive Graham Copley. These collaborations have contributed to the advancement of his research and the successful development of his patents.
Conclusion
Michael Derek Edge is a distinguished inventor whose work in monoclonal antibodies has the potential to significantly impact cancer treatment. His innovative approaches and collaborations highlight his commitment to advancing medical science.